Table 1.

Baseline and longitudinal features of the total population.

	T0	T1	T2	T3	T4	T5	Χ2	p
Number of patients	117	99	90	72	58	46	n.a.	n.a.
Prepubertal (%)	87/117 (74%)	59/99 (60%)	45/90 (50%)	23/72 (32%)	14/58 (24%)	0/46 (0%)	51.57	<0.05a
Male (%)	61/117 (52%)	51/99 (51%)	45/90 (50%)	39/72 (54%)	30/58 (52%)	19/46 (41%)	1.12	0.95
CA (years)	8.67 ± 3.33	9.68 ± 3.38	10.49 ± 3.33	11.25 ± 3.34	11.92 ± 3.06	15.64 ± 1.49	164.04	<0.05a
BA (years)	7.94 ± 3.15	9.06 ± 3.25	9.85 ± 3.58	10.81 ± 3.98	12.44 ± 3.21	14.97 ± 1.36	23.09	0.00012a
BA delay (years)	–1.07 ± 1.09	–0.89 ± 1.10	–0.77 ± 1.01	–0.67 ± 1.33	–0.32 ± 1.19	n.a.	5.82	0.21
H SDS	–2.37 ± 0.67	–1.91 ± 0.64	–1.64 ± 0.73	–1.45 ± 0.62	–1.39 ± 0.64	–1.65 ± 0.94	107.14	<0.05a
BMI SDS	–0.07 ± 0.94	–0.09 ± 0.97	–0.05 ± 1.01	–0.13 ± 0.92	–0.02 ± 0.84	0.28 ± 1.04	13.19	0.02
GV SDS	–1.37 ± 1.65	1.85 ± 2.08	1.32 ± 2.23	0.99 ± 2.02	0.36 ± 2.19	–0.99 ± 2.21	18.27	0.002a
Arm span/H ratio	0.97 ± 0.07	0.98 ± 0.13	0.97 ± 0.03	0.97 ± 0.03	0.97 ± 0.04	0.97 ± 0.02	2.13	0.83
Sitting H/H ratio	0.56 ± 0.02	0.56 ± 0.05	0.55 ± 0.02	0.55 ± 0.01	0.55 ± 0.02	0.56 ± 0.02	19.36	0.0016a
Sitting H/H ratio SDS	2.19 ± 1.27	2.12 ± 1.35	2.10 ± 1.31	2.10 ± 1.28	2.11 ± 1.37	2.24 ± 1.12	9.74	0.08
Rappold’s score	7.51 ± 4.86	7.72 ± 5.10	7.14 ± 5.67	7.08 ± 5.41	6.35 ± 5.36	7.57 ± 5.66	1.24	0.94
Tibial varus (%)	35/101 (34%)	38/69 (55%)	32/79 (40%)	28/65 (43%)	24/50 (48%)	22/42 (52%)	9.12	0.34
Muscular pseudohypertrophy (%)	45/100 (45%)	42/71 (59%)	36/80 (45%)	28/65 (43%)	21/50 (42%)	2/4 (50%)	7.3	0.56
High-arched palate (%)	15/89 (17%)	12/73 (16%)	12/67 (18%)	10/53 (19%)	8/38 (21%)	1/4 (25%)	4.5	0.67
rhGH dose (mg/kg/week)	0.23 ± 0.04	0.24 ± 0.05	0.24 ± 0.06	0.24 ± 0.06	0.24 ± 0.06	n.a.	4.97	0.28
IGF1 SDS	–0.99 ± 0.93	0.69 ± 1.30	0.87 ± 1.20	0.95 ± 1.42	1.16 ± 1.17	n.a.	48.56	<0.05a

^aP < 0.05 from longitudinal analysis (T0 –T5) using Friedman ANOVA test. Bold values represent statistical significance.